| SB431542 |
drug |
6 |
5 |
SB, TGFβ inhibitor SB431542 |
| scalp potentials |
phenotype |
2 |
— |
reference-dependent scalp potentials |
| SCD |
gene |
2 |
1 |
stearoyl-CoA desaturase |
| Scd1 |
gene |
2 |
2 |
SCD1, Scd1, Stearoyl-CoA desaturase 1, human SCD1, stearoyl CoA desaturase 1 |
| schizoaffective disorder |
phenotype |
16 |
4 |
SCHIZOAF, schizoaffective, schizoaffective concept, schizoaffective disorder |
| schizoid personality disorder |
phenotype |
5 |
3 |
Schizoid PD, schizoid PD, schizoid personality disorder |
| schizophrenia |
phenotype |
201 |
136 |
DSM-III-R schizophrenia, F20, MIM 181500, SC, SCH, SCZ, SCZD, SZ, Schizophrenia, adult schizophrenia brains, family history of schizophrenia, genetic or clinical risk for schizophrenia, individuals with schizophrenia, patients with schizophrenia, psychotic disorder, schizophrenia, schizophrenia cohort, schizophrenia diagnosis, schizophrenia patients, schizophrenia subjects, schizophrenia susceptibility, schizophrenia-like illness, schizophrenia-like symptoms, schizophrenic, schizophrenic patients, schizophrenics |
| schizophrenia GWAS |
cohort |
2 |
2 |
|
| schizophrenia polygenic risk score |
cohort |
2 |
3 |
PRS, SCZ PRS, genetic risk for schizophrenia, polygenic liability for schizophrenia, polygenic risk for SCZ, polygenic risk for schizophrenia, schizophrenia polygenic risk |
| schizophreniform disorder |
phenotype |
2 |
1 |
|
| schizotypal personality disorder |
phenotype |
3 |
1 |
SPD, Schizotypal, Schizotypal PD, schizotypal PD |
| Schizotypy |
phenotype |
2 |
1 |
|
| school |
phenotype |
2 |
2 |
|
| school performance |
phenotype |
5 |
3 |
poor performance in school, school |
| school problems |
phenotype |
2 |
1 |
school |
| SCID |
cohort |
2 |
1 |
|
| scientists |
cohort |
2 |
1 |
|
| Scn1a |
gene |
3 |
— |
sodium channel, voltage-gated, type I, alpha subunit |
| Scn8a |
gene |
4 |
1 |
Nav1.6, Scn8a |
| scopolamine |
drug |
3 |
3 |
muscarinic antagonist |
